Repatha and Type 1 diabetes - a phase IV clinical study of FDA data

Summary:

Type 1 diabetes is reported as a side effect among people who take Repatha (evolocumab), especially for people who are female, 60+ old, also take Prolia, and have Arteriosclerosis coronary artery.

The phase IV clinical study analyzes which people have Type 1 diabetes when taking Repatha. It is created by eHealthMe based on reports of 155,838 people who have side effects when taking Repatha from the FDA, and is updated regularly.

What is Repatha?

Repatha has active ingredients of evolocumab. It is often used in high blood cholesterol. eHealthMe is studying from 156,258 Repatha users. Check the latest studies of Repatha.

What is Type 1 diabetes?

Type 1 diabetes is found to be associated with 668 drugs and 1,644 conditions by eHealthMe. Check the latest studies of Type 1 diabetes.

On May, 17, 2026

155,838 people reported to have side effects when taking Repatha.
Among them, 13 people (0.01%) have Type 1 diabetes.

Among these 13 people:

What is the gender of people who have Type 1 diabetes when taking Repatha? *

female: 53.85 %
male: 46.15 %

What is the age of people who have Type 1 diabetes when taking Repatha? *

What are other drugs people take besides Repatha? *

Prolia: 2 people, 15.38%
Praluent: 1 person, 7.69%

What are other side effects people have besides Type 1 diabetes? *

Itching: 2 people, 15.38%
Injection Site Bruising: 2 people, 15.38%
Tendon Pain: 1 person, 7.69%
Staphylococcal Infection (an infection with staphylococcus bacteria): 1 person, 7.69%
Neuralgia (pain in one or more nerves): 1 person, 7.69%
Muscle Enzyme Increased: 1 person, 7.69%
Muscle Aches (muscle pain): 1 person, 7.69%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 7.69%
Insomnia (sleeplessness): 1 person, 7.69%
Infection: 1 person, 7.69%

What are the existing conditions these people have? *

Arteriosclerosis Coronary Artery (thickening and hardening of arteries- coronary artery): 2 people, 15.38%
Arterial Occlusive Disease (slow process through which arteries throughout the body become progressively narrowed and eventually completely blocked): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Repatha and have Type 1 diabetes?

- Check whether Type 1 diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Repatha:

Repatha (156,258 reports)

Type 1 diabetes treatments and more:

Type 1 diabetes (46,846 reports)

Browse all side effects of Repatha:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type 1 diabetes:

Type 1 diabetes (668 drugs)

Browse all the conditions that are associated with Type 1 diabetes:

Type 1 diabetes (1,644 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on evolocumab (the active ingredients of Repatha) and Repatha (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.